Group One Trading, L.P. Krystal Biotech, Inc. Transaction History

Group One Trading, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$108.01 - $179.35 $128,747 - $213,785	1,192 New	1,192 $212,000
Q1 2022 May 12, 2022	SELL	$51.99 - $72.11 $24,175 - $33,531	-465 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$39.81 - $88.24 $18,511 - $41,031	465 New	465 $33,000
Q2 2021 Aug 10, 2021	SELL	$62.14 - $81.82 $34,549 - $45,491	-556 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$59.42 - $85.46 $9,269 - $13,331	156 Added 39.0%	556 $43,000
Q3 2020 Nov 12, 2020	BUY	$37.76 - $48.49 $3,776 - $4,849	100 Added 33.33%	400 $17,000
Q2 2020 Aug 13, 2020	BUY	$37.03 - $60.0 $11,109 - $18,000	300 New	300 $12,000

311

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.07B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.